JBS Science, con sede en Pensilvania, dijo hoy que recibió el premio Bridge Award for Small Business Innovation Research IIB de $ 3 millones del Instituto Nacional del Cáncer. La empresa desarrolló el primer producto de biopsia líquida, que es la detección de ADN en orina para detectar cáncer temprano de células hepáticas (CHC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of cáncer de hígado. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS dijo que ha cooperado con James Hamilton del Centro Médico de la Universidad Johns Hopkins y Hie-Won Hann del Hospital Universitario Thomas para avanzar en el desarrollo de una prueba de orina para el cáncer de hígado.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
